Proven & Trusted
Experts
Pioneering Life-Saving Innovation in Sepsis Treatment
OUR START
PATH EX was founded in 2017 by Sinead Miller and Alex Wieseler in Nashville, TN. Since inception, the company has been focused on bringing its revolutionary medical device, CycloPE® to market, offering a potentially live-saving solution to patients suffering from sepsis. In 2018, the company was part of the ZeroTo510 Medical Device accelerator in Memphis, TN. Additionally, the company has been a part of MedTech Innovator and the Texas Medical Center accelerators. In 2019, the company moved to Houston, TX to be a resident at Johnson & Johnson’s site for innovation, JLABS.
PATH EX has been supported by both government grants and venture funding. PATH EX received NSF STTR Phase I and NSF Phase II grants from the National Science Foundation for development of the CycloPE® device.
OUR PRODUCT
Revolutionizing Sepsis Treatment — CycloPE® represents a paradigm shift in the treatment of sepsis: instead of just managing symptoms, we are removing the root cause.
PATH EX, Inc. has developed CycloPE®, a medical device designed to directly capture and remove bacteria from the bloodstream, providing a rapid, targeted solution for the treatment of sepsis. The company has secured FDA Breakthrough Device Designation and successfully completed preclinical and clinical feasibility studies demonstrating promising outcomes. PATH EX is now advancing toward FDA approval and commercialization.
Meet The Team
At PATH EX, our strength lies in the expertise and vision of our team. Led by a passionate management group with deep scientific, clinical, and business experience, and supported by seasoned board members and world-class scientific advisors, we bring together the skills needed to advance life-saving medical technologies. From groundbreaking biomedical research to proven success in medical device commercialization and clinical trial leadership, our team is united by a shared commitment to transforming patient care.
MANAGEMENT TEAM
Sinead Miller is the Cofounder and CEO of PATH EX. Sinead earned her Ph.D. in Biomedical Engineering from Vanderbilt University, where her research focused on developing technologies for pathogen detection and removal, laying the foundation for PATH EX’s novel approach to blood filtration. Sinead is passionate about translating cutting-edge science into life-saving technologies and plays a central role in guiding PATH EX’s strategic direction, clinical trial development, and regulatory strategy.
Alex Wieseler is the Cofounder and COO of PATH EX. With an MBA and a background in international finance, Alex guides the company’s business operations, ensuring a strong financial foundation for growth and expansion. Alex’s role at PATH EX extends beyond finance, as he provides strategic leadership across the company’s fundraising efforts, investor relations, and long-term business development. His experience has been instrumental in aligning the company’s business goals with its product development and clinical objectives, helping to position PATH EX as an emerging company in the medical device industry.
BOARD MEMBERS
Ehsan is a board member at PATH EX, a Partner at IAG Capital Partners, and a Full Professor of Chemical and Biomedical Engineering and Director of Engineering Entrepreneurship at the University of South Carolina. As an entrepreneur, he co-founded and led Obsidio Inc (acquired by Boston Scientific), a venture-backed medical device company that pioneered a biomaterial technology to block blood flow with applications in hemorrhage control and interventional oncology. Ehsan brings extensive knowledge in strategic medical device development and commercialization.
Jeff Burbank is a board member at PATH EX, the Chief Executive Officer of NxStage Medical Inc., and a member of the Board of Directors. Jeff has over 30 years of in-depth management experience with companies developing, marketing, and manufacturing products for ESRD patients. He has led NxStage since its inception, guiding it through all of its developmental phases to the successful initiation and rapid growth of commercial activities, its initial public offering, the acquisition of Medisystems Corporation, the evolution of the product line, and into services. Jeff brings years of experience in the development, production, and commercialization of medical devices.
SCIENTIFIC ADVISORS
Jamie Dwyer is an advisor for PATH EX. He is a practicing nephrologist and Associate Dean for Clinical Research at the University of Utah Health. With extensive experience in clinical trial development, Jamie provides valuable guidance in shaping the design and execution of PATH EX’s clinical trials. He has served on multiple Executive and Steering Committees for large-scale trials and was appointed as a Consultant to the FDA’s CardioRenal Advisory Committee. His deep knowledge of clinical research and healthcare systems helps PATH EX navigate the complexities of trial design, patient recruitment, and regulatory pathways, ensuring the device’s success in the clinical validation process.
Farzad Soleimani serves as an advisor to PATH EX, bringing his expertise as a practicing intensivist and Healthcare Partner at 1984 Ventures. Farzad plays a key role in guiding PATH EX from both a clinical and business development standpoint. He is the founder of eTherapi, a pioneering telemedicine company, and the founding co-director of the Texas Medical Center Biodesign Innovation Program. Farzad’s clinical insights and strategic business experience help PATH EX navigate the various aspects of device development, helping to position the company for success.
BOARD OBSERVERS
Emily Reiser is the Director of Strategy and New Ventures at the Texas Medical Center (TMC), where she contributes to the Texas Medical Center Venture Fund and other strategic projects across TMC. In previous roles at TMC, Emily has spearheaded accelerator programs in cancer therapeutics and healthtech, led the recruitment of entrepreneurs in residence, and supported BioBridge global relationships. Prior to TMC, Emily contributed to the launch of Houston-based medtech startup, Noleus Technologies. Emily earned her bachelor’s degree in Biology from Emory University and a PhD in Bioengineering from Rice University, where her research focused on drug delivery for cancer immunotherapy.
Mark Poag is a Board Observer at PATH EX, a General Partner at Fitz Gate Ventures, and a successful software entrepreneur that helped lead a company from start-up, through rapid growth, market dominance and ultimate strategic sale. Mark has first-hand experience of what it takes to start, grow and sell a successful business. Mark teaches venture capital investing as an Adjunct Professor at the Rice University Jones Graduate School of Business and as a Lecturer at Princeton University’s Graduate School where he won the Clio Hall Award. He is Co-Chair of the Princeton University Alumni Schools Committee of Houston and the former President of the Princeton Alumni Association of Houston.
Anna is a board observer at PATH EX and an analyst at IAG Capital Partners. Her bioengineering background began at Vanderbilt University and was followed by a master’s from Imperial College London. She gained experience in medical device research and design during her academic career.
